Artelo Capital Surpluse from 2010 to 2024

ARTL Stock  USD 1.11  0.02  1.77%   
Artelo Biosciences Capital Surpluse yearly trend continues to be quite stable with very little volatility. Capital Surpluse may rise above about 12.4 M this year. From the period between 2010 and 2024, Artelo Biosciences, Capital Surpluse regression line of its data series had standard deviation of  5,387,739 and standard deviation of  5,387,739. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
11.8 M
Current Value
12.4 M
Quarterly Volatility
5.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Artelo Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artelo Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.3 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.46. Artelo financial statements analysis is a perfect complement when working with Artelo Biosciences Valuation or Volatility modules.
  
Check out the analysis of Artelo Biosciences Correlation against competitors.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.

Latest Artelo Biosciences' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Artelo Biosciences over the last few years. It is Artelo Biosciences' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Artelo Biosciences' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Artelo Capital Surpluse Regression Statistics

Arithmetic Mean4,596,413
Geometric Mean597,869
Coefficient Of Variation117.22
Mean Deviation5,035,544
Median827,940
Standard Deviation5,387,739
Sample Variance29T
Range12.4M
R-Value0.90
Mean Square Error6T
R-Squared0.81
Slope1,082,550
Total Sum of Squares406.4T

Artelo Capital Surpluse History

202412.4 M
202311.8 M
201910.3 M
20182.5 M
2017827.9 K

About Artelo Biosciences Financial Statements

Artelo Biosciences investors utilize fundamental indicators, such as Capital Surpluse, to predict how Artelo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse11.8 M12.4 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Artelo Biosciences is a strong investment it is important to analyze Artelo Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Artelo Biosciences' future performance. For an informed investment choice regarding Artelo Stock, refer to the following important reports:
Check out the analysis of Artelo Biosciences Correlation against competitors.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.87)
Return On Assets
(0.54)
Return On Equity
(0.89)
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.